Sativa Investments has unique position in the UK market
By in

Sativa Investments has unique position in the UK market

Sativa Investments PLC’s Geremy Thomas tells Proactive that the medicinal cannabis market has seen explosive growth all over the world, particularly in Vancouver, Canada.

He adds that Sativa has a unique position in the UK market that allows UK investors to benefit from companies in regulated markets.

Read the full article here

Watch the full video interview with CEO Geremy Thomas.

Rapid Dose Therapeutics
By in

Rapid Dose Therapeutics

Rapid Dose Therapeutics, RDT, is a Canadian bio-technology company which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes.

Formed because of a recognized need to move drug delivery to a new level. RDT provides product innovation, production, and consultation to the pharmaceutical and healthcare manufacturing industry.

RDT Technology

Proprietary oral fast-dissolving drug delivery system, QuickStrip™, rapidly releases an expansive list of pharmaceuticals, emulsified oils, and a host of over-the-counter medicines. This permits API’s to enter the blood stream through a rapid dose pathway without being degraded or modified by first pass metabolism in the liver.

How rapid is a Rapid Dose Therapeutic? Studies show the QuickStrip™ technology delivery mimics blood concentrations over time to intravenous injection.

Sublingual and transmucosal transport of active molecules result from the rapid dissolution of QuickStrip™ combined with the proprietary technology.

By in ,

Sativa invests C$ 0.2 million in Canadian-based Rapid Dose Therapeutics Inc

Press Release                                                                                                                                                          23 May 2018


The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.


Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa invests C$ 0.2 million in Canadian-based Rapid Dose Therapeutics Inc. which owns QuickStrip™ oral technology for medicinal cannabis use


Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, has subscribed to, through a private placement which may or may not precede an IPO, 400,000 shares at C$ 0.50 per share, at a cost of C$ 0.2 million cash, in Toronto-based Pharma-Tech company, Rapid Dose Therapeutics Inc. (“RDT”). 

RDT has its own patent-pending proprietary QuickStrip™ technology, a fast-dissolving strip that is placed on or under the tongue, or inside the cheek, then enters directly in to the recipient’s system, mimicking an injection path.  Pharmaceuticals, emulsified oils and over-the-counter medicines are used in RDT’s proprietary RDMx mixture technology, which is sold across North America.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said:  “RDT’s technology delivers medicinal cannabis bypassing the normal oral or inhaler delivery and, as such, is an exceptional way of ingesting the therapy, is easy to administer, provides a consistent and rapid dose, and is likely to improve patient outcomes.

“The dynamic medicinal cannabis market in Canada has allowed RDT to develop this CBD product to be absorbed directly in to a person’s system.”

Mark Upsdell, Chief Executive Officer of Rapid Dose Therapeutics, said: “Our proprietary formulation for the mixture of various medicines and pharmaceuticals to be administered through our QuickStrip™ technology, has led to RDT using CBD medicinal cannabis in QuickStrip™. 

“We are delighted to have entered in to this new relationship with Sativa.  RDT looks forward working together with Sativa in this fast developing market to unlock the potential for our products in the UK and Europe.”

–  Ends  –

For more information please contact:


Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255


NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930


Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630


Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: